BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 33115829)

  • 1. Distinct Genomic Alterations in Prostate Tumors Derived from African American Men.
    Liu W; Zheng SL; Na R; Wei L; Sun J; Gallagher J; Wei J; Resurreccion WK; Ernst S; Sfanos KS; Isaacs WB; Xu J
    Mol Cancer Res; 2020 Dec; 18(12):1815-1824. PubMed ID: 33115829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic Profiling of Prostate Cancers from Men with African and European Ancestry.
    Koga Y; Song H; Chalmers ZR; Newberg J; Kim E; Carrot-Zhang J; Piou D; Polak P; Abdulkadir SA; Ziv E; Meyerson M; Frampton GM; Campbell JD; Huang FW
    Clin Cancer Res; 2020 Sep; 26(17):4651-4660. PubMed ID: 32651179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrative comparison of the genomic and transcriptomic landscape between prostate cancer patients of predominantly African or European genetic ancestry.
    Yuan J; Kensler KH; Hu Z; Zhang Y; Zhang T; Jiang J; Xu M; Pan Y; Long M; Montone KT; Tanyi JL; Fan Y; Zhang R; Hu X; Rebbeck TR; Zhang L
    PLoS Genet; 2020 Feb; 16(2):e1008641. PubMed ID: 32059012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel genomic alteration of LSAMP associates with aggressive prostate cancer in African American men.
    Petrovics G; Li H; Stümpel T; Tan SH; Young D; Katta S; Li Q; Ying K; Klocke B; Ravindranath L; Kohaar I; Chen Y; Ribli D; Grote K; Zou H; Cheng J; Dalgard CL; Zhang S; Csabai I; Kagan J; Takeda D; Loda M; Srivastava S; Scherf M; Seifert M; Gaiser T; McLeod DG; Szallasi Z; Ebner R; Werner T; Sesterhenn IA; Freedman M; Dobi A; Srivastava S
    EBioMedicine; 2015 Dec; 2(12):1957-64. PubMed ID: 26844274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
    Hamid AA; Gray KP; Shaw G; MacConaill LE; Evan C; Bernard B; Loda M; Corcoran NM; Van Allen EM; Choudhury AD; Sweeney CJ
    Eur Urol; 2019 Jul; 76(1):89-97. PubMed ID: 30553611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic, epigenomic, and transcriptomic signatures of prostate cancer between African American and European American patients.
    Stevens C; Hightower A; Buxbaum SG; Falzarano SM; Rhie SK
    Front Oncol; 2023; 13():1079037. PubMed ID: 36937425
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Faisal FA; Murali S; Kaur H; Vidotto T; Guedes LB; Salles DC; Kothari V; Tosoian JJ; Han S; Hovelson DH; Hu K; Spratt DE; Baras AS; Tomlins SA; Schaeffer EM; Lotan TL
    Clin Cancer Res; 2020 Jun; 26(11):2595-2602. PubMed ID: 31969336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer.
    Yamoah K; Johnson MH; Choeurng V; Faisal FA; Yousefi K; Haddad Z; Ross AE; Alshalafa M; Den R; Lal P; Feldman M; Dicker AP; Klein EA; Davicioni E; Rebbeck TR; Schaeffer EM
    J Clin Oncol; 2015 Sep; 33(25):2789-96. PubMed ID: 26195723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations.
    Böttcher R; Kweldam CF; Livingstone J; Lalonde E; Yamaguchi TN; Huang V; Yousif F; Fraser M; Bristow RG; van der Kwast T; Boutros PC; Jenster G; van Leenders GJLH
    BMC Cancer; 2018 Jan; 18(1):8. PubMed ID: 29295717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions.
    Kluth M; Hesse J; Heinl A; Krohn A; Steurer S; Sirma H; Simon R; Mayer PS; Schumacher U; Grupp K; Izbicki JR; Pantel K; Dikomey E; Korbel JO; Plass C; Sauter G; Schlomm T; Minner S
    Mod Pathol; 2013 Jul; 26(7):975-83. PubMed ID: 23370768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D.
    Simbolo M; Mafficini A; Sikora KO; Fassan M; Barbi S; Corbo V; Mastracci L; Rusev B; Grillo F; Vicentini C; Ferrara R; Pilotto S; Davini F; Pelosi G; Lawlor RT; Chilosi M; Tortora G; Bria E; Fontanini G; Volante M; Scarpa A
    J Pathol; 2017 Mar; 241(4):488-500. PubMed ID: 27873319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.
    Beltran H; Yelensky R; Frampton GM; Park K; Downing SR; MacDonald TY; Jarosz M; Lipson D; Tagawa ST; Nanus DM; Stephens PJ; Mosquera JM; Cronin MT; Rubin MA
    Eur Urol; 2013 May; 63(5):920-6. PubMed ID: 22981675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early-onset metastatic and clinically advanced prostate cancer is a distinct clinical and molecular entity characterized by increased TMPRSS2-ERG fusions.
    Chalmers ZR; Burns MC; Ebot EM; Frampton GM; Ross JS; Hussain MHA; Abdulkadir SA
    Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):558-566. PubMed ID: 33420417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced immortalization, HUWE1 mutations and other biological drivers of breast invasive carcinoma in Black/African American patients.
    Andey T; Attah MM; Akwaaba-Reynolds NA; Cheema S; Parvin-Nejad S; Acquaah-Mensah GK
    Gene; 2020 Dec; 763S():100030. PubMed ID: 34493366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
    Manzano RG; Catalan-Latorre A; Brugarolas A
    BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatic mutations in the DNA repairome in prostate cancers in African Americans and Caucasians.
    Yadav S; Anbalagan M; Baddoo M; Chellamuthu VK; Mukhopadhyay S; Woods C; Jiang W; Moroz K; Flemington EK; Makridakis N
    Oncogene; 2020 May; 39(21):4299-4311. PubMed ID: 32300177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Copy number and gene expression differences between African American and Caucasian American prostate cancer.
    Rose AE; Satagopan JM; Oddoux C; Zhou Q; Xu R; Olshen AB; Yu JZ; Dash A; Jean-Gilles J; Reuter V; Gerald WL; Lee P; Osman I
    J Transl Med; 2010 Jul; 8():70. PubMed ID: 20649978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole-exome Sequencing of Nigerian Prostate Tumors from the Prostate Cancer Transatlantic Consortium (CaPTC) Reveals DNA Repair Genes Associated with African Ancestry.
    White JA; Kaninjing ET; Adeniji KA; Jibrin P; Obafunwa JO; Ogo CN; Mohammed F; Popoola A; Fatiregun OA; Oluwole OP; Karanam B; Elhussin I; Ambs S; Tang W; Davis M; Polak P; Campbell MJ; Brignole KR; Rotimi SO; Dean-Colomb W; Odedina FT; Martin DN; Yates C
    Cancer Res Commun; 2022 Sep; 2(9):1005-1016. PubMed ID: 36922933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic profiling of prostate cancers from African American men.
    Castro P; Creighton CJ; Ozen M; Berel D; Mims MP; Ittmann M
    Neoplasia; 2009 Mar; 11(3):305-12. PubMed ID: 19242612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole-exome sequencing in osteosarcoma reveals important heterogeneity of genetic alterations.
    Bousquet M; Noirot C; Accadbled F; Sales de Gauzy J; Castex MP; Brousset P; Gomez-Brouchet A
    Ann Oncol; 2016 Apr; 27(4):738-44. PubMed ID: 26787232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.